XNASVIGL
Market cap75mUSD
Jan 08, Last price
1.84USD
1D
-4.66%
1Q
-45.56%
IPO
-83.87%
Name
Vigil Neuroscience Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
Net income
-83m
L+22.02%
CFO
-70m
L+8.00%
Profile
Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed on myeloid cells 2 (TREM2) which is in Phase I for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, as well as for the treatment of cerebral adrenoleukodystrophy and alzheimer's disease. The company also develops a small molecule TREM2 agonist suitable for oral delivery to treat common neurodegenerative diseases associated with microglial dysfunction. Vigil Neuroscience, Inc. was incorporated in 2020 and is headquartered in Cambridge, Massachusetts.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY |
|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | |
| Income | ||||
Revenues | ||||
Cost of revenue | 89,265 | 69,894 | ||
Unusual Expense (Income) | ||||
NOPBT | (89,265) | (69,894) | ||
NOPBT Margin | ||||
Operating Taxes | ||||
Tax Rate | ||||
NOPAT | (89,265) | (69,894) | ||
Net income | (82,638) 22.02% | (67,726) 56.58% | ||
Dividends | ||||
Dividend yield | ||||
Proceeds from repurchase of equity | 911 | 140,466 | ||
BB yield | -0.70% | -35.47% | ||
| Debt | ||||
Debt current | 1,810 | 176 | ||
Long-term debt | 26,795 | 329 | ||
Deferred revenue | ||||
Other long-term liabilities | 1,965 | |||
Net debt | (89,335) | (187,027) | ||
| Cash flow | ||||
Cash from operating activities | (70,363) | (65,149) | ||
CAPEX | (674) | (921) | ||
Cash from investing activities | (65,138) | (921) | ||
Cash from financing activities | 888 | 161,255 | ||
FCF | (105,747) | (70,079) | ||
| Balance | ||||
Cash | 117,940 | 186,605 | ||
Long term investments | 927 | |||
Excess cash | 117,940 | 187,532 | ||
Stockholders' equity | (222,773) | 60,263 | ||
Invested Capital | 353,780 | 128,994 | ||
ROIC | ||||
ROCE | ||||
| EV | ||||
Common stock shares outstanding | 38,712 | 31,685 | ||
Price | 3.38 -72.96% | 12.50 | ||
Market cap | 130,847 -66.96% | 396,064 | ||
EV | 41,512 | 409,430 | ||
EBITDA | (88,866) | (69,816) | ||
EV/EBITDA | ||||
Interest | ||||
Interest/NOPBT | ||||